1. Coltman CA. Chemotherapy of advansed Hodgkin’s lymphoma. Semin Oncol 1980; 7: 155–73.
2. Diehl V, Behringer K. Could BEACOPP Be the New Standard for the Treatment of Advanced Hodgkin’s Lymphoma? Cancer Investigation 2006; 24: 261–5.
3. Cancer. Principles & Practice of Oncology. 3rd ed. Eds. V.T.DeVita, S.Hellman, S.A.Rosenberg. Philadelphia: Lippincott-Raven Publishers, 1989; 1696–739.
4. De Vita VT, Serpick AA. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Am Assoc Cancer Res 1967; 8: 13.
5. De Vita VT, Simon RM, Hubbard SM et al. Currability of advanced Hodgkin’s disease with chemotherapy. Long-term follow up of MOPP treated patients at NCI. Ann Intern Med 1980; 92: 587–95.
6. Zeller P, Gutmann H, Hegedus B et al. Methylhydrazine derivates. a new class of cytotoxic agents. Experimenta 1963; 19: 129.
7. Newell D, Gescher A, Harland S et al. N-methyl antitumor agents: a distinct class of anticancer drags? Cancer Chemother Pharmacol 1987; 19: 91–102.
8. Erikson JM, Tweedie DJ, Ducore JM et al. Cytotoxicity and DNA damage caused by the azoxy metabolites of procarbazine in L1210 tumor cells. Cancer Res 1989; 49: 127–33.
9. Armand J-P, Ribrag V, Harrouseau J-L et al. Reppraisal of the Use of Procarbasine in the Treatment of Lymphomas and Brain Tumors. Ther Clin Risk Manag 2007; 3 (2): 213–24.
10. Brunner KW, Yong CW. A methylhydrazine derivative in Hodgkin’s disease and other malignant neoplasms. Therapeutic and toxic effects studied in 51patients. Ann Intern Med 1965; 63: 69–86.
11. Preiss R, Baumann F, Regenthal R et al. Plasma kinetics of procarbazine and azo- procarbazine in humans. Anti-Cancer Drugs 2006; 17: 75–80.
12. Bonadonna G. Histirical review of Hodgkin’s disease. Brit J Haematol 2000; 110: 504–11.
13. Ng AK, Bernardo MV, Weller W et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989–6.
14. Hodgkin’s disease. Ed. P.V.Mauch, J.O.Armitage, V.Diehl et al. Philadelphia, 2007.
15. Bramswig JH, Hornig-Franz I, Riepenhausen M et al. The challenge of pediatric Hodgkin’s disease – where is the balance between cure and Long-term toxicity? A report of the West German Multicenter Studies DAL-HD-78, DAL-HD-82, DAL-HD-85. Leuk Lymphoma 1990; 2: 183.
16. Schelong G, Bramswig JH, Hornig-Franz I et al. Treatment of children with Hodgkin’s disease. Results of the German Pediatric Oncology Group. Ann Oncol 1992; 3: S73.
17. Bonnadonna G, Zucaly R, Monfardini S et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–9.
18. Federico M, Luminary S, Dell’Olio M et al., ABVD vs. COPPTBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin lymphoma (HL)/Preliminary results of HD2000 GISL trail. Haematologica 2007; s5: 34 abstr C026.
19. Diehl V, Franklin J, Hasenclever D et al. BEACOPP: A new regimen for advanced stage Hodgkin’s disease. Ann Oncol 1998; 9 (Suppl. 5): 67–71.
20. Franklin J, Diehl V. Сurrent clinical trails for the treatment of advanced stage Hodgkin’s disease: BEACOPP. Ann Oncol 2002; 13 (Suppl. 1): 98–101.
21. De Bruin ML, Huisbrink JM, Hauptmann M et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008; 111: 101–8.
22. Sieniawski М, Reineke Т, Nogova L et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71–6.
23. Sieber M, Bredenfeld H, Josting A et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin,Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of aPilot Study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003; 21: 1734–9.
24. Hampton T. Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies; JAMA 2008; 299 (5): 510–2 (doi: 10.1001/jama.299.5.510).
25. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo studio dei Linfomi Trial. J Clin Oncol 2009; 5.
Авторы
Е.А.Демина
ГУ Онкологический научный центр им. Н.Н.Блохина РАМН, Москва